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A comprehensive systematic review has recommended decreasing the number of individuals who receive 
treatment for subclinical hypothyroidism; however, data included in the study are extremely limited for young 
individuals. Extrapolating data from older individuals is perhaps unwise; therefore, the onus should be on the 
urgent need for further research. 
 
Decreased thyroid function is seen in subclinical hypothyroidism (SCH), which is defined by elevated TSH and 
normal free thyroid hormone levels and is regularly encountered by clinicians. We therefore read with interest a 
BMJ Rapid Recommendation, by Geertruida Bekkering and colleagues1, in which the authors indicate a strong 
recommendation against the use of levothyroxine replacement in adults with SCH. Key caveats were that this 
recommendation should not apply to women who are trying to become pregnant (or who are currently 
pregnant), those with severe symptoms or patients with TSH levels of >20 mIU/l. This TSH threshold is somewhat 
higher than previous international guidelines from the American and European Thyroid Associations2,3, which 
advocated treatment at TSH levels >10 mIU/l, with a trial of treatment to be considered in symptomatic 
individuals at lower TSH thresholds. 
 
Given that SCH is present in up to 10% of the population, the present guidance1 will affect a large number of 
people, especially females3. The difficulty for clinicians is that SCH has been associated with adverse 
cardiovascular, metabolic, mood and pregnancy outcomes, but the benefits of treatment with levothyroxine are 
unclear4. The Bekkering guidance1 was based on a 2018 systematic review5 of 21 randomized controlled trials in 
patients with SCH. While we recognize the value and the effort undertaken in these analyses1,5, we feel it is 
important to moderate the conclusions regarding TSH threshold at treatment initiation. 
 
As Bekkering and colleagues note, the studies included in the systematic review5 were small — the 21 clinical 
trials studied contained only 2,192 participants. These clinical trials were varied with regard to TSH threshold 
required for treatment initiation and age of the participants. In addition, a third of all the patients studied in the 
review (n = ϳ3ϳͿ weƌe fƌoŵ the TRUST study6 and ~75% of the participants with quality of life assessments were 
from this one study. The TRUST study was originally intended to be a cardiovascular trial, and as such focused on 
patients >65 years old (mean age in the trial was 74.4 years). Furthermore, based on the quality of life measures 
used in TRUST, hypothyroid symptoms at baseline were similar to those reported in patients with hypothyroidism 
who had already been treated with levothyroxine. Thus, improvements in symptoms might not have been 
expected in this largely asymptomatic population. TSH thresholds were also modest; the baseline median TSH 
was ϱ.ϳϲ ŵU/l ;iŶteƌƋuaƌtile ƌaŶge 5.10–6.94 mU/l) in the placebo group and 5.73 mU/l (interquartile range 5.12–
6.83 mU/l) in the treatment group. Therefore, the TRUST trial provides information only on older individuals with 
mild SCH and symptoms. 
 
It is increasingly recognized that increased levels of TSH might be a normal part of ageing, with the upper 97.5% 
confidence interval for serum levels of TSH in healthy elderly persons being ~7.5 mIU/l (ref.7). This important 
consideration does not seem to have been taken into account by the authors of this guidance1. Given that many 
individuals in the TRUST study6 are likely to have had normal age-adjusted thyroid function, it is perhaps 
unsurprising that the authors of the TRUST study found no evidence of treatment benefit. Therefore, it would 
seem to be unwise to extrapolate these findings to individuals who are <65 years old, as in this demographic 
elevations in TSH are not yet within the reference range. This point is particularly important as observational data 
do show increased adverse cardiovascular outcomes in SCH at TSH levels >10.0 mIU/l (ref.8) and there seems to 
be an age interaction with regard to treatment with benefits seen in those aged <65 years9. 
 
The guidance from Bekkering and colleagues1 does point out that quality of life findings were similar1 when the 
TRUST study was removed from analyses. However, by removing the TRUST trial, the problem now becomes lack 
of power. When TRUST is excluded from the review, there are only 423 participants in whom quality of life or 
cognition were studied, as several other studies focused on other factors such as BMI. Based on the baseline data 
of these studies5, only a small proportion of these 423 participants would have an age <40 years or TSH levels 
>8.0 mIU/l. Furthermore, owing to the nature of the studies included, the quality of life assessments have 
incorporated heterogeneous measures that assess general health status, and screening tools for minor 
psychiatric disorders; this incorporation has both weakened the power and confidence we can have in the 
guidance for quality of life. Only a small number of patients with TSH levels of >10 mIU/l have been studied in a 
randomized manner5 and health-care professionals should communicate the uncertainty around the data to 
patients rather than raising the TSH threshold to a very high threshold of 20 mIU/l. 
 
We welcome the caveat in the present guidance, which states that the guidance should not apply to women who 
are pregnant or to those who are planning pregnancy. However, given that many pregnancies are unplanned, this 
guidance might still expose women of child-bearing age to substantial hypothyroidism and substantial 
hypothyroidism in early pregnancy, with clear potential for adverse obstetric and offspring outcomes. We also 
agree that over-treatment with levothyroxine can lead to adverse outcomes as the authors highlight, but sensible 
monitoring and patient education can mitigate this. It would seem logical that concerns regarding potential over-
treatment should not solely prevent treatment initiation. 
 
Taken together, we are concerned that based on the present guidance1, treatment might be erroneously denied 
to symptomatic or young individuals with SCH. The caveat for severe symptoms might mitigate this, but younger 
individuals with TSH levels >10 mIU/l and only moderate symptoms would be denied treatment. For instance, 
many endocrinologists would find it very hard to justify denial of a trial of levothyroxine treatment to a 
symptomatic 44-year-old female with a TSH of 9.5 mIU/l or an asymptomatic 35-year-old woman with no clear 
pregnancy plans and a TSH of 19.0 mIU/l, although these patients would now be recommended not to receive 
treatment, according to this guidance. What the clearly summarized and presented systematic review5 and 
guidance1 do highlight is the paucity of high-quality evidence in this area. This lack of evidence is both surprising 
and highly regrettable as SCH is so common and because many patients have persistent concerns and 
dissatisfaction with their thyroid hormone replacement10. 
 
We strongly believe that a much more important conclusion from this work is that carefully conducted trials of 
SCH are urgently needed. Such trials need to be an order of magnitude larger than previous studies, focus on 
younger individuals and control for other factors, such as inter-individual genetic variation when ascertaining 
treatment response. In addition to TSH, other biomarkers of tissue hypothyroidism need to be identified. Further 
work is needed on assessing thyroid hormone replacement itself, in particular the potential role of combination 
thyroid hormone replacement with liothyronine and levothyroxine. Thus, urgent research action is needed, not 
clinical inaction. 
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